GET DAILY SIGNALSWhy Is Legend Biotech Corporation (LEGN) Stock Down -9.18% Today?
Key Takeaways
- Shares of LEGN dropped 9.18% to $22.06, down from Monday's close of $24.29, after gapping lower to $20.66 at the opening bell.
- Third-quarter revenue of $359.5 million, up 32% year over year, landed essentially in line with consensus, while U.S. CARVYKTI sales growth decelerated to 19% from 32% in the prior quarter.
- Profit-taking compounded the slide: the stock had rallied 42.9% from its mid-September low to Monday's $24.29 close, leaving little room for a merely in-line quarter.
- Broader biotech benchmarks fell less than 1%, confirming the selloff was company-specific rather than sector-driven.
- News Significance Score: 50/100 - Modest earnings news met a decline more than three times the stock's typical daily swing.
- Traders are now watching fourth-quarter gross margin guidance in the high-50% range, sequential global CARVYKTI growth, and ASH data in December.
- Detailed Price Targets, Earnings and Forecast pages offer deeper context on the company's outlook.
- For systematic exposure, explore Trending AI Robots.
Opening Summary
Legend Biotech Corporation (LEGN) is a global cell-therapy company whose lead product, CARVYKTI, is a one-time CAR-T treatment for relapsed multiple myeloma developed and sold with Johnson & Johnson (JNJ). Its American depositary shares fell 9.18% to $22.06 on Tuesday, down from Monday's completed close of $24.29, after trading as low as $20.66 shortly after the open. The decline followed third-quarter results published before the opening bell that showed a swing to profit but revenue roughly in line with expectations and a marked slowdown in U.S. sales growth — a combination that triggered a sell-the-news reaction after a six-week rally.
Third-Quarter Results: Profit Improves, Growth Decelerates
Legend reported total revenue of $359.5 million, up 32% from $272.4 million a year earlier but essentially level with the roughly $358.6 million consensus. Net income reached $51.7 million, or $0.13 per ordinary share, against a net loss of $39.6 million a year ago, while adjusted net income of $55.6 million ($0.14 per diluted ADS) met expectations.
CARVYKTI net trade sales rose 36% year over year to about $710 million across 373 active treatment sites in 20 markets. Gross margin improved to 58% from a guided low-50% range, and management guided fourth-quarter gross margin on net product sales to the high-50% range. Operating income of $46.8 million compared with a $43.3 million operating loss a year earlier, though results included a $24 million one-time share-based compensation credit; excluding it, operating margin was about 6%.
Decelerating Growth in the Core U.S. Market
The detail that drove the negative market reaction was the composition of growth. U.S. CARVYKTI net trade sales grew 19% year over year and were roughly flat sequentially, a sharp deceleration from the 32% U.S. growth recorded in the second quarter, when total revenue rose 52%. The 86% international growth that carried the quarter reflects newer launches rather than the mature, higher-margin U.S. base.
That mix shift matters because the bull case rests on CARVYKTI taking share in second- and third-line myeloma, where 50% of U.S. apheresis volume now sits, up from 41% in the first quarter. Investors had already been debating competitive pressure from newer BCMA-directed therapies, and a quarter that confirmed volume expansion abroad while U.S. momentum cooled gave cautious holders a reason to reduce exposure.
Profit-Taking After a 43% Run Into the Print
Positioning amplified the move. From a closing low of $17.00 on September 16, the shares climbed 42.9% to $24.29 on November 9, including four of the final five sessions. With the stock approaching territory last seen before the summer's 52-week high near $37.50, expectations were elevated heading into the release, and an in-line quarter was insufficient to sustain the rally. The result was a classic sell-the-news session rather than a fundamental re-rating.
Market Context and Trading Activity
Trading was heavy relative to recent norms: roughly 240,000 shares changed hands in the first eight minutes, about a fifth of the 70-session average daily volume of approximately 1.13 million shares. Broad biotech benchmarks slipped only about 0.8% to 0.9%, and JNJ was marginally lower, so the stock's decline was more than ten times the sector's drift.
Technically, the gap lower pushed shares below the $21 mark for the first time since late October and briefly under the 50-day and 200-day moving averages near $21 and $22, before buyers lifted the price back above $22. The intraday range of $20.66 to $22.12 shows dip-buying interest emerging at lower levels.
News Significance Score
The scale runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 50 out of 100.
The verified news was moderate: a quarterly report with revenue in line with consensus, adjusted earnings matching expectations, and no change to full-year profitability targets. Against a roughly $4.4 billion market capitalization, that is material but not transformative. The price move was 9.18%, about 3.2 times the stock's typical absolute daily move of 2.8%, and the largest single-session swing in at least 60 sessions — no session in that window matched it. Moderate news plus an unusually large move combine into the mid-range score.
What Comes Next for LEGN
Attention shifts to fourth-quarter gross margin execution, which management guided to the high-50% range, and to whether U.S. CARVYKTI demand reaccelerates as community treatment centers come online. The company still targets company-wide profitability on an adjusted net income basis for full-year 2026, with about $853 million in cash and time deposits providing runway. Legend will present seven abstracts at the ASH Annual Meeting from December 12 to 15, including CARTITUDE-4 subgroup analyses and updated LB2501 in-vivo CAR-T data. Risks include competitive pressure, quarter-to-quarter margin variability, and dilution from this year's equity raises.
Trending AI Robots
Tickeron's Trending AI Robots page curates the strongest-performing automated trading bots under current market conditions from a library of hundreds of systems spanning thousands of tickers. Bots differ by strategy, timeframe, performance metrics and the symbols they trade, so the featured lineup rotates as market conditions change. Reviewing this page can help traders compare live strategies and identify approaches that fit their own time horizon and risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
LEGN in upward trend: 10-day moving average crossed above 50-day moving average on October 28, 2026
The 10-day moving average for LEGN crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on LEGN as a result. In 77 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
LEGN moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +7.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where LEGN advanced for three days, in 176 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LEGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
LEGN broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.701) is normal, around the industry mean (3.498). P/E Ratio (-46.800) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.478) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. LEGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LEGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company which engages in the discovery and development of novel cell therapies for oncology and other indications
Industry Biotechnology
Advertisement